Companies in #Hidradenitis Suppurativa
Found 2 companies operating in this sector.
Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1beta-based treatments for immune-mediated inflammatory diseases. Its lead asset, abdakibart (AVTX-009), is a humanised monoclonal antibody that binds interleukin-1beta with high affinity, and the company is developing it principally in hidradenitis suppurativa, where a Phase 2 trial read out positively and a Phase 3 programme is being planned. Avalo was incorporated in 2011 as Cerecor Inc. and renamed Avalo Therapeutics in August 2021, refocusing on immunology after divesting its earlier paediatric and rare-disease assets. The company raised approximately $375 million in a May 2026 underwritten public offering priced at $17.75 per share to fund the abdakibart programme, and it reports substantial cash relative to its operating spend. Avalo is headquartered in Wayne, Pennsylvania and trades on the Nasdaq under the ticker AVTX.
Turn Therapeutics is a clinical-stage biotechnology company developing targeted, localized, non-systemic therapies for inflammatory and infectious skin diseases. Its lead program, GX-03, is a topical IL-36/IL-31 pathway inhibitor in Phase 2 for moderate-to-severe atopic dermatitis; a July 2026 interim analysis supported expanding Stage 2 enrollment to roughly 120-135 patients, with topline data targeted for Q4 2026 and a Phase 2a study in hidradenitis suppurativa planned. The company's PermaFusion formulation platform is being developed with Medline under a global supply, development and license agreement, and supports a thermostable intranasal vaccine initiative. Turn Therapeutics (formerly Global Health Solutions, renamed in September 2025) completed a direct listing on Nasdaq in October 2025 and named former FDA Commissioner Stephen M. Hahn as Executive Clinical and Regulatory Lead in May 2026.